GlaxoSmithKline PLC — Regulatory Filings 2017

Oct 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 13 October 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the ' Company ')

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms E Walmsley | |
| --- | --- | --- | --- |
| b) | Position
/ status | Chief
Executive Officer | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 14 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr R G Connor | |
| --- | --- | --- | --- |
| b) | Position
/ status | President, Global Manufacturing & Supply | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 57 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr S Dingemans | |
| --- | --- | --- | --- |
| b) | Position
/ status | Chief Financial Officer | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 20 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr N Hirons | |
| --- | --- | --- | --- |
| b) | Position
/ status | SVP, Global Ethics & Compliance | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 7 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D S Redfern | |
| --- | --- | --- | --- |
| b) | Position
/ status | Chief Strategy Officer | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 65 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms C Thomas | |
| --- | --- | --- | --- |
| b) | Position
/ status | SVP, Human Resources | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 65 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr P C Thomson | |
| --- | --- | --- | --- |
| b) | Position
/ status | President,
Global Affairs | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 35 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr P J T Vallance | |
| --- | --- | --- | --- |
| b) | Position
/ status | President, R&D | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 39 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mrs V A Whyte | |
| --- | --- | --- | --- |
| b) | Position
/ status | Company Secretary | |
| c) | Initial
notification / amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of
the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature of the
transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 October 2017, on shares held
through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | £15.2816 | 46 |
| d) | Aggregated
information Aggregated
volume Price | n/a (single transaction) | |
| e) | Date
of the transaction | 2017-10-12 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: October
13, 2017
By: VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break